Modality
Radioligand
MOA
BiTE
Target
FXIa
Pathway
Ferroptosis
CeliacGIST
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
Nov 2022
→ Feb 2029
Phase 1Current
NCT06213875
1,854 pts·GIST
2022-11→2026-03·Not yet recruiting
NCT03909438
2,322 pts·Celiac
2024-09→2029-02·Recruiting
4,176 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-103w agoPh2 Data· GIST
2029-02-222.9y awayPh2 Data· Celiac
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2026-03-10 · 3w ago
GIST
Ph2 Data
2029-02-22 · 2.9y away
Celiac
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06213875 | Phase 1/2 | GIST | Not yet recr... | 1854 | ACR20 |
| NCT03909438 | Phase 1/2 | Celiac | Recruiting | 2322 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Rimaosocimab | Amgen | Preclinical | FXIa |